- Home
- AERO vs ATAI Comparison
AERO vs ATAI Comparison
Compare AERO & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AERO | ATAI |
|---|---|---|
| Founded | 1934 | 2018 |
| Country | Mexico | United States |
| Employees | 17068 | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | AERO | ATAI |
|---|---|---|
| Price | $15.19 | $7.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $28.57 | $15.88 |
| AVG Volume (30 Days) | 287.8K | ★ 10.4M |
| Earning Date | 04-21-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,089,000.00 |
| Revenue This Year | $11.85 | N/A |
| Revenue Next Year | $4.57 | N/A |
| P/E Ratio | $7.95 | ★ N/A |
| Revenue Growth | N/A | ★ 1227.60 |
| 52 Week Low | $12.26 | $3.06 |
| 52 Week High | $23.05 | $7.22 |
Technical Indicators
Market Signals| Indicator | AERO | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 36.13 | 73.17 |
| Support Level | $14.46 | $3.56 |
| Resistance Level | $17.17 | N/A |
| Average True Range (ATR) | 0.76 | 0.36 |
| MACD | -0.23 | 0.22 |
| Stochastic Oscillator | 12.85 | 97.14 |
Price Performance
Historical ComparisonAbout AERO Grupo Aeromexico S.A.B.
Grupo Aeromexico SAB de CV engages in providing air transport services for passengers, goods, and cargo, as well as loyalty program services, training and management services, franchise systems commercialization, and the management of investment in shares. Its services include passenger and cargo transportation, the Club Premier loyalty program, training, charter services, and other aviation-related activities. The company operates through a single operating segment, air transportation, and its geographical presence includes both domestic and international markets, with the majority of revenue coming from the international market.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.